Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations
Authors:
- 21 June 2011
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 35 (12) , 1611-1615
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotypeLeukemia Research, 2004
- FLT3 mutations in childhood acute lymphoblastic leukemiaBlood, 2004
- Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patientsEuropean Journal of Haematology, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Acute myeloid leukemia in the older patientCritical Reviews in Oncology/Hematology, 2003
- Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.2003
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group UlmBlood, 2002
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisBlood, 2002
- FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemiaBlood, 2001